Home / Pharmaceuticals / Hypercalcemia Treatment Market By Drug Class (Bisphosphonates, Calcimimetic Agents, Calcitonin, Denusomab, Glucocorticoids) - Growth, Future Prospects & Competitive Analysis, 2018 - 2026

Hypercalcemia Treatment Market By Drug Class (Bisphosphonates, Calcimimetic Agents, Calcitonin, Denusomab, Glucocorticoids) - Growth, Future Prospects & Competitive Analysis, 2018 - 2026

Published: Apr 2018 | Report Code: 59106-04-18

Industry Outlook

The global hypercalcemia treatment market will reach US$ 23,707.8 Mn by 2026 from US$ 9,544.1 Mn in 2017, growing at a CAGR of 10.7% during the forecast period from 2018 to 2026. Hypercalcemia is a condition characterized by the elevated levels of serum calcium ranging above 2.6 mmol/L. The disorder is predominantly associated with two main causes including hypercalcemia of malignancy (HCM) and primary hyperparathyroidism. The disorder occurs in 10% to 20% of the cancer patients, prominently in the breast and lung cancer patients. Furthermore, other factors responsible for hypercalcemia are hereditary factors, severe dehydration, medications, and supplements. The global hypercalcemia treatment market will surge during the forecast period pertaining to the rising number of cancer patients, growing prevalence of hyperparathyroidism-related hypercalcemia, and availability of appropriate drug treatment therapies. Furthermore, rising incidence of multiple myeloma, availability of drug therapy alternatives over surgeries and favorable reimbursement policies in developed countries including the United States expected to fuel global market.

As generics dominates the market, label extension of the drugs for the treatment of more indications further expected to contribute to the growth of the market. The key market players are particularly focusing on the chronic kidney disease (CKD) along with the parathyroidism. For instance, US FDA approved a drug manufactured by OPKO Health for the treatment of secondary hyperparathyroidism in adults with CKD. Such approvals will propel the growth of global hypercalcemia market.

Market Synopsis

Hypercalcemia Treatment Market

Bisphosphonates expected to retain major market share during the forecast period

Bisphosphonates is the major segment capturing over 65% of market value share. Bisphosphonates are used to prevent the loss of bone density. Due to the high preference of bisphosphonates, the segment will retain its supremacy in the market during the forecast period. Furthermore, the usage of combination therapy for the treatment of hypercalcemia is increasing, which combines two or more drugs from same or different classes. The high preference of combination therapy in developed country further fuels the growth of bisphosphonates market as these drugs are used predominantly in combination therapy with other drugs and therapies. For instance, many researchers and physicians are evaluating the use of combination of pamidronate and calcitonin. Denusomab market segment will be the fastest growing market segment during the forecast period followed by calcitonin. The aforementioned treatment pattern adopted by physicians is expected to catalyze the growth of hypercalcemia drugs market.

Hypercalcemia Treatment Market

Asia Pacific to Experience Lucrative Growth with Double Digit CAGR during the Forecast Period

The Asia Pacific expected to witness lucrative growth during the forecast period owing to high awareness and rising adoption of the hypercalcemia treatment drugs. Furthermore, increasing prevalence of hyperparathyroidism-related hypercalcemia and growing incidence of multiple myeloma in the region expected to fuel the market. Additionally, the rising accessibility of drug therapies and favorable reimbursement policies in the developing countries further contributes to the double-digit growth of the Asia Pacific market.

In 2017, North America dominated the hypercalcemia treatment market with over 34% of the market share, in terms of market value. The United States expected to dominate the North America market due to high awareness regarding hypercalcemia and associated disorders. Furthermore, growing prevalence of malignancy-related hypercalcemia among cancer patients will further catalyze the growth of the North America hypercalcemia market.

Hypercalcemia Treatment Market

Approval of Promising Pipeline Candidates Expected to Fuel the Market Growth

The global hypercalcemia treatment market is highly fragmented due to the presence of numerous players. However, some of the players dominated the market attributing to the development of effective drugs, novel product launches, and strategic market initiatives. Furthermore, the unmet needs of the disease compel manufacturers to focus on R&D and develop products that are more efficient. For instance, Kyowa Hakko Kirin Co., Ltd. has completed phase III clinical trials for KHK7580 and filled a NDA (New Drug Application) in Japan. Furthermore, the manufacturers is developing another candidate, KRN1493, for secondary hyperparathyroidism. Expected approval of such promising candidates will fuel the market during the forecast period. Additionally, key players in hypercalcemia market include Novartis AG, Amgen, Inc., Teva Pharmaceuticals Industries Ltd., F.Hoffmann-La Roche Ltd., Kyowa Hakko Kirin, OPKO Health, Merck & Co., Abbive, Inc., and Pfizer, Inc.

Hypercalcemia Treatment Market

Historical & Forecast Period

2016 – Historical Year

2017 – Base Year

2018-2026 – Forecast Period

The hypercalcemia market is scrutinized considering 2017 as the base year for the research and CAGRs are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

This holistic research study on hypercalcemia treatment market present the current market dynamics and outlook. The research study is conducted at granular level by segmenting the market in terms of drug class and geography.

Hypercalcemia Treatment Market

  • Drug Class Segment (2016–2026; US$ Mn)
    • Bisphosphonates
      • Clodronate
      • Etidronate
      • Ibandronate
      • Pamidronate
      • Zoledronic acid
    • Calcitonin
    • Glucocorticoids
    • Calcimimetic agents
    • Denusomab
    • Pipeline Analysis
      • Phase III (Market Estimations up to 2026)
        • KHK7580
      • Phase II & I (Qualitative Information)
  • Geography Segment (2016–2026; US$ Mn)
    • North America
      • United States
      • Canada
    • Europe
      • United Kingdom
      • Germany
      • Rest of Europe
    • Asia Pacific (APAC)
      • Japan
      • China
      • Rest of APAC
    • Latin America (LATAM)
      • Brazil
      • Mexico
      • Rest of LATAM
    • Middle East and Africa (MEA)
      • GCC
      • Rest of MEA

This research study further elucidates the key qualitative market assessment parameters including key market trends, DROs, to assist in holistic understanding of global hypercalcemia treatment market. Additionally, the major players are mapped graphically based on their business strength, market strategies and product offering. The research study further provides attractive investment proposition based on the extensive geographical research. Major manufacturers profiled in the report include AbbVie, Inc., Merck & Co., OPKO Health, Novartis AG, Amgen, Inc., Teva Pharmaceuticals Industries Ltd., F.Hoffmann-La Roche Ltd., Kyowa Hakko Kirin and Pfizer, Inc.

Key questions answered in this report

  • Which are the predominant drug classes or drugs prescribed as the first line treatment in hypercalcemia?
  • How pipeline products approval affect the market in Japan?
  • What are the current market trends in the hypercalcemia treatment industry and attractive investments for the players?
  • Which is the fastest growing regional market?
  • What proportion of global hypercalcemia treatment market is held by North America, and how the other regional markets stand in the global competition?
  • Which countries in Asia Pacific considered predominant during the geographical outreach?

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Market Segmentation
1.3 Research Scope
1.4 Research Methodology
1.4.1 Phase I – Secondary Research
1.4.2 Phase II – Primary Research
1.4.3 Phase III – Expert Panel Review
1.4.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Hypercalcemia Treatment Market Portraiture
2.2 Global Hypercalcemia Treatment Market, by Drug Class, 2017 (US$ Mn)
2.3 Global Hypercalcemia Treatment Market, by Geography, 2017 (US$ Mn)

Chapter 3 Global Hypercalcemia Treatment Market: Dynamics & Future Outlook
3.1 Market Overview
3.2 Market Dynamics
3.2.1 Drivers
3.2.1.1 Adoption of Combination Therapy in Treatment of Hypercalcemia
3.2.1.2 Rising Prevalence of Malignancy and Hyperparathyroidism-related Hypercalcemia
3.2.2 Challenges
3.2.2.1 Challenge 1
3.2.3 Opportunities
3.2.3.1 Opportunity 1
3.3 Attractive Investment Proposition, by Geography, 2017
3.4 Competitive Landscape, by Key Players, 2017

Chapter 4 Global Hypercalcemia Treatment Market, by Drug Class, 2016-2026 (US$ Mn)
4.1 Overview
4.2 Bisphosphonates
4.2.1 Clodronate
4.2.2 Etidronate
4.2.3 Ibandronate
4.2.4 Pamidronate
4.2.5 Zoledronic acid
4.3 Calcimimetic Agents
4.4 Calcitonin
4.5 Denusomab
4.6 Glucocorticoids
4.7 Pipeline Analysis
4.7.1 Phase III
4.7.1.1 KHK7580
4.7.2 Phase II & I (Tabular Information)

Chapter 5 Global Hypercalcemia Treatment Market, by Geography, 2016-2026 (US$ Mn)
5.1 Overview
5.2 North America Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
5.2.1 North America Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
5.2.2 North America Hypercalcemia Treatment Market, by Country, 2016–2026 (US$ Mn)
5.2.2.1 United States
5.2.2.2 Canada
5.3 Europe Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
5.3.1 Europe Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
5.3.2 Europe Hypercalcemia Treatment Market, by Country/Region, 2016–2026 (US$ Mn)
5.3.2.1 United Kingdom
5.3.2.2 Germany
5.3.2.3 Rest of Europe
5.4 Asia Pacific Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
5.4.1 Asia Pacific Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
5.4.2 Asia Pacific Hypercalcemia Treatment Market, by Country/Region, 2016–2026 (US$ Mn)
5.4.2.1 Japan
5.4.2.2 China
5.4.2.3 Rest of Asia Pacific
5.5 Latin America Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
5.5.1 Latin America Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
5.5.2 Latin America Hypercalcemia Treatment Market, by Country/Region, 2016–2026 (US$ Mn)
5.5.2.1 Brazil
5.5.2.2 Mexico
5.5.2.3 Rest of LATAM
5.6 Middle East & Africa Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
5.6.1 Middle East & Africa Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
5.6.2 Middle East & Africa Hypercalcemia Treatment Market, by Region, 2016–2026 (US$ Mn)
5.6.2.1 GCC
5.6.2.2 Rest of MEA

Chapter 6 Company Profiles
6.1 Amgen, Inc.
6.1.1 Business Description
6.1.2 Financial Information
6.1.3 Product Portfolio
6.1.4 Key Developments
6.2 Bayer Pharma AG
6.3 Cipla, Inc.
6.4 Dr. Reddy’s Laboratories, Ltd.
6.5 Mylan N.V.
6.6 Novartis AG
6.7 Pfizer, Inc.
6.8 Sun Pharmaceutical Industries, Ltd.

FIG. 1 Market Segmentation: Global Hypercalcemia Treatment Market
FIG. 2 Global Hypercalcemia Treatment Market: Research Methodology
FIG. 3 Global Hypercalcemia Treatment Market, by Drug Class, 2017 (US$ Mn)
FIG. 4 Global Hypercalcemia Treatment Market, by Geography, 2017 (US$ Mn)
FIG. 5 Attractive Investment Proposition, by Geography, 2017
FIG. 6 Competitive Analysis: Global Hypercalcemia Treatment Market, by Key Players, 2017
FIG. 7 Global Clodronate Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 8 Global Etidronate Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 9 Global Ibandronate Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 10 Global Pamidronate Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 11 Global Zoledronic acid Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 12 Global Calcimimetic Agents Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 13 Global Calcitonin Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 14 Global Denusomab Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 15 Global Glucocorticoids Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 16 Global KHK7580 Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 17 U.S. Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 18 Canada Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 19 U.K. Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 20 Germany Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 21 Rest of Europe Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 22 Japan Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 23 China Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 24 Rest of Asia Pacific Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 25 Brazil Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 26 Mexico Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 27 Rest of Latin America Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 28 GCC Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 29 Rest of Middle East & Africa Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)

TABLE 1 Global Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 2 Global Bisphosphonates Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
TABLE 3 Global Hypercalcemia Treatment Market, by Geography, 2016–2026 (US$ Mn)
TABLE 4 Hypercalcemia Phase II & I Drugs Tabular Information
TABLE 5 North America Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 6 North America Hypercalcemia Treatment Market, by Country, 2016–2026 (US$ Mn)
TABLE 7 Europe Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 8 Europe Hypercalcemia Treatment Market, by Country, 2016–2026 (US$ Mn)
TABLE 9 Asia Pacific Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 10 Asia Pacific Hypercalcemia Treatment Market, by Country, 2016–2026 (US$ Mn)
TABLE 11 Latin America Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 12 Latin America Hypercalcemia Treatment Market, by Country, 2016–2026 (US$ Mn)
TABLE 13 Middle East & Africa Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 14 Middle East & Africa Hypercalcemia Treatment Market, by Region, 2016–2026 (US$ Mn)
TABLE 15 Amgen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Bayer Pharma AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Cipla, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Dr. Reddy’s Laboratories, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Mylan N.V.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Sun Pharmaceutical Industries, Ltd: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients